Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.

Mansi Bhurani,Lorenz Admojo,Carrie van der Weyden,Robert Twigger,Ali Bazargan,Hang Quach,Allan Zimet,Luke Coyle,Julian Lindsay,Dejan Radeski,Eliza A Hawkes,Glen A. Kennedy,Ian Irving,Naadir Gutta,Judith Trotman,James Yeung,Lindsay Dunlop,Minh Hua,Pratyush Giri,Sam Yuen,Shyam Panicker,Susan Moreton,Liane Khoo,Ashleigh Scott,David Kipp,Andrew McQuillan,Christopher McCormack,Michael Dickinson,Henry Miles Prince

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.

2020

We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic th...

Keywords:

T-cell lymphoma
Internal medicine
Cutaneous T-cell lymphoma
Oncology
Lymphoma
Cohort
Peripheral T-cell lymphoma
Mucositis
Medicine
Pralatrexate
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations